naltrexone has been researched along with gabapentin in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (33.33) | 29.6817 |
| 2010's | 15 (55.56) | 24.3611 |
| 2020's | 3 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Jolivette, LJ; Ward, KW | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Andoh, T; Kuraishi, Y; Nojima, H; Shiraki, K; Takasaki, I | 1 |
| Castellano, M; Cervera, G; Martínez-Raga, J; Perez-Galvez, B; Sabater, A | 1 |
| Freye, E; Levy, JV; Partecke, L | 1 |
| Acosta, GB; Baratti, CM; Blake, MG; Boccia, MM | 1 |
| Anton, RF; Baros, AM; Latham, PK; Myrick, H; Randall, PK; Waid, LR; Wright, TM | 1 |
| O'Brien, CP | 1 |
| Kremer, AE; Mettang, T | 1 |
| Ciudad, N; Lux, S; Miranda, HF; Noriega, V; Prieto, JC; Sierralta, F; Troncoso, R; Zanetta, P; Zepeda, R | 1 |
| Lyon, J | 1 |
| Alto, W; Gianutsos, P; Mancl, L; Plawman, A; Rudolf, G; Rudolf, V; Walsh, J | 1 |
| Ahmad, SU; Kumar, J; Mohamed, IN; Pakri Mohamed, RM | 1 |
| Guitart, J; Martinez-Escala, ME; Serrano, L; Zhou, XA | 1 |
| Castañeda-Hernández, G; Chávez-Piña, AE; Landa-Juárez, AY; Ortiz, MI; Pérez-Severiano, F | 1 |
| Alho, H; Castrén, S; Mäkelä, N | 1 |
| Hulme, J; Sheikh, H; Wiercigroch, D | 1 |
| Fomin, V; Goodman, RP; Luther, J; Patel, SJ; Schaefer, E; Shay, JES; Vannier, AGL | 1 |
| Andreiev, AI; Chopra, N; Costa, T; George, TP; Ledwos, N | 1 |
5 review(s) available for naltrexone and gabapentin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Uremic pruritus.
Topics: Acupuncture Therapy; Amines; Anti-Inflammatory Agents; Calcium Channel Blockers; Cyclohexanecarboxylic Acids; Gabapentin; gamma-Aminobutyric Acid; gamma-Linolenic Acid; Humans; Morphinans; Naltrexone; Narcotic Antagonists; Pentoxifylline; Phototherapy; Pregabalin; Pruritus; Receptors, Opioid, kappa; Renal Insufficiency, Chronic; Spiro Compounds; Tacrolimus; Thalidomide; Uremia | 2015 |
Novel Pharmacotherapeutic Approaches in Treatment of Alcohol Addiction.
Topics: Alcohol Deterrents; Alcoholism; Animals; Aripiprazole; Baclofen; Cyclopentanes; Gabapentin; Humans; Naltrexone; Quetiapine Fumarate | 2018 |
Pruritus in Cutaneous T-Cell Lymphoma and Its Management.
Topics: Adrenal Cortex Hormones; Amines; Antidepressive Agents, Tricyclic; Antipruritics; Cyclohexanecarboxylic Acids; Emollients; Gabapentin; gamma-Aminobutyric Acid; Histamine Antagonists; Humans; Lymphoma, T-Cell, Cutaneous; Naltrexone; Narcotic Antagonists; Neurokinin-1 Receptor Antagonists; Pruritus; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Surveys and Questionnaires; Visual Analog Scale | 2018 |
Selecting an appropriate alcohol pharmacotherapy: review of recent findings.
Topics: Acamprosate; Alcoholism; Antidepressive Agents; Baclofen; Cholinergic Agonists; Disulfiram; Gabapentin; Humans; Naltrexone; Ondansetron; Randomized Controlled Trials as Topic; Treatment Outcome | 2019 |
3 trial(s) available for naltrexone and gabapentin
| Article | Year |
|---|---|
Add-on gabapentin in the treatment of opiate withdrawal.
Topics: Acetates; Adult; Amines; Cyclohexanecarboxylic Acids; Excitatory Amino Acid Antagonists; Female; Gabapentin; gamma-Aminobutyric Acid; Heroin; Heroin Dependence; Humans; Male; Naltrexone; Narcotic Antagonists; Narcotics; Recurrence; Substance Withdrawal Syndrome | 2004 |
Use of gabapentin for attenuation of symptoms following rapid opiate detoxification (ROD)--correlation with neurophysiological parameters--.
Topics: Acetates; Adult; Amines; Anesthesia; Anesthetics, Intravenous; Cyclohexanecarboxylic Acids; Electric Stimulation; Evoked Potentials, Somatosensory; Excitatory Amino Acid Antagonists; Female; Gabapentin; gamma-Aminobutyric Acid; Heroin Dependence; Hormone Antagonists; Humans; Magnesium; Male; Median Nerve; Methadone; Naltrexone; Narcotic Antagonists; Narcotics; Potassium; Propofol; Restless Legs Syndrome; Somatostatin; Substance Withdrawal Syndrome; Water-Electrolyte Balance | 2004 |
Gabapentin combined with naltrexone for the treatment of alcohol dependence.
Topics: Adult; Alcohol Drinking; Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug Therapy, Combination; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Male; Middle Aged; Naltrexone; Narcotic Antagonists; Secondary Prevention; Substance Withdrawal Syndrome; Treatment Outcome | 2011 |
19 other study(ies) available for naltrexone and gabapentin
| Article | Year |
|---|---|
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
Gabapentin antinociception in mice with acute herpetic pain induced by herpes simplex virus infection.
Topics: Acetates; Amines; Analgesics; Animals; Behavior, Animal; Cyclohexanecarboxylic Acids; Drug Tolerance; Female; Gabapentin; gamma-Aminobutyric Acid; Herpes Simplex; Herpesvirus 1, Human; Hyperalgesia; Mice; Mice, Inbred BALB C; Motor Activity; Naltrexone; Narcotic Antagonists; Pain | 2001 |
Posttraining administration of pentylenetetrazol dissociates gabapentin effects on memory consolidation from that on memory retrieval process in mice.
Topics: Amines; Animals; Anticonvulsants; Avoidance Learning; Behavior, Animal; Convulsants; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Drug Interactions; Gabapentin; gamma-Aminobutyric Acid; Male; Memory; Mice; Mice, Inbred Strains; Naltrexone; Narcotic Antagonists; Pentylenetetrazole; Reaction Time; Retention, Psychology; Time Factors | 2004 |
Adapting treatment to patient problems.
Topics: Alcoholism; Amines; Cyclohexanecarboxylic Acids; Drug Administration Schedule; Drug Therapy, Combination; Gabapentin; gamma-Aminobutyric Acid; Humans; Naltrexone; Research Design; Sertraline | 2011 |
Involvement of nitridergic and opioidergic pathways in the antinociception of gabapentin in the orofacial formalin test in mice.
Topics: Amines; Analgesics; Animals; Cyclohexanecarboxylic Acids; Dose-Response Relationship, Drug; Gabapentin; gamma-Aminobutyric Acid; Male; Mice; Naltrexone; Narcotic Antagonists; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Pain Measurement; Signal Transduction | 2015 |
More Treatments on Deck for Alcohol Use Disorder.
Topics: Acamprosate; Alcohol Deterrents; Alcohol-Related Disorders; Amines; Baclofen; Cyclohexanecarboxylic Acids; Cytidine Diphosphate Choline; Disulfiram; Drug Repositioning; Fructose; Gabapentin; gamma-Aminobutyric Acid; Humans; Mifepristone; Naltrexone; National Institute on Alcohol Abuse and Alcoholism (U.S.); Off-Label Use; Patient Acceptance of Health Care; Taurine; Topiramate; United States; Varenicline | 2017 |
A novel non-opioid protocol for medically supervised opioid withdrawal and transition to antagonist treatment.
Topics: Adult; Amines; Analgesics, Opioid; Buprenorphine; Clonidine; Counseling; Cyclohexanecarboxylic Acids; Female; Gabapentin; gamma-Aminobutyric Acid; Humans; Hydroxyzine; Male; Naltrexone; Narcotic Antagonists; Opiate Substitution Treatment; Opioid-Related Disorders; Retrospective Studies; Substance Withdrawal Syndrome; Treatment Outcome; Young Adult | 2018 |
The antihyperalgesic effect of docosahexaenoic acid in streptozotocin-induced neuropathic pain in the rat involves the opioidergic system.
Topics: Analgesics; Analgesics, Opioid; Animals; Diabetic Neuropathies; Docosahexaenoic Acids; Dose-Response Relationship, Drug; Gabapentin; Naloxone; Naltrexone; Rats; Rats, Wistar; Receptors, Opioid, kappa; Receptors, Opioid, mu; Receptors, sigma; Streptozocin | 2019 |
A rapid access to addiction medicine clinic facilitates treatment of substance use disorder and reduces substance use.
Topics: Acamprosate; Addiction Medicine; Adult; Aged; Alcohol Deterrents; Alcoholism; Buprenorphine; Emergency Service, Hospital; Female; Gabapentin; Humans; Male; Middle Aged; Naltrexone; Ontario; Opioid-Related Disorders; Patient Acceptance of Health Care; Primary Health Care; Referral and Consultation; Socioeconomic Factors; Substance Abuse Treatment Centers; Substance-Related Disorders; Time Factors; Young Adult | 2020 |
Incidence and Progression of Alcohol-Associated Liver Disease After Medical Therapy for Alcohol Use Disorder.
Topics: Alcoholism; Baclofen; Female; Gabapentin; Humans; Incidence; Liver Cirrhosis; Male; Middle Aged; Naltrexone; Retrospective Studies; Topiramate | 2022 |
Successful treatment of dextromethorphan use disorder with combined naltrexone and gabapentin: a case report.
Topics: Dextromethorphan; Gabapentin; Humans; Naltrexone | 2023 |